Omnipaque 140 and Fibrosis - a phase IV clinical study of FDA data

Summary:

Fibrosis is reported as a side effect among people who take Omnipaque 140 (iohexol), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Omniscan, and have Joint deposit.

The phase IV clinical study analyzes which people have Fibrosis when taking Omnipaque 140. It is created by eHealthMe based on reports of 1,105 people who have side effects when taking Omnipaque 140 from the FDA, and is updated regularly.

What is Omnipaque 140?

Omnipaque 140 has active ingredients of iohexol. eHealthMe is studying from 1,106 Omnipaque 140 users. Check the latest studies of Omnipaque 140.

What is Fibrosis?

Fibrosis (formation of excess fibrous connective tissue in an organ or tissue) is found to be associated with 691 drugs and 682 conditions by eHealthMe. Check the latest studies of Fibrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

1,105 people reported to have side effects when taking Omnipaque 140.
Among them, 11 people (1.0%) have Fibrosis.

Among these 11 people:

How long have people been on Omnipaque 140 when they have Fibrosis? *

What is the gender of people who have Fibrosis when taking Omnipaque 140? *

female: 90 %
male: 10 %

What is the age of people who have Fibrosis when taking Omnipaque 140? *

What are other drugs people take besides Omnipaque 140? *

What are other side effects people have besides Fibrosis? *

Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 10 people, 90.91%
Pain: 10 people, 90.91%
Rashes (redness): 10 people, 90.91%
Skin Induration (an abnormally hard spot or area on the skin): 10 people, 90.91%
Skin Exfoliation (removal of the oldest dead skin cells): 10 people, 90.91%
Oedema Peripheral (superficial swelling): 10 people, 90.91%
Scar: 9 people, 81.82%
Deformity (disfigurement): 9 people, 81.82%
Pain Of Skin: 9 people, 81.82%
Joint Stiffness: 9 people, 81.82%

What are the existing conditions these people have? *

Synovitis (inflammation of the synovial membrane): 5 people, 45.45%
Joint Deposit (deposit in joint): 5 people, 45.45%
Nuclear Magnetic Resonance Imaging Brain: 4 people, 36.36%
Rash Pruritic (redness with itching): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Omnipaque 140 and have Fibrosis?

- Check whether Fibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Omnipaque 140:

Omnipaque 140 (1,106 reports)

Fibrosis treatments and more:

Fibrosis (4,958 reports)

Browse all side effects of Omnipaque 140:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fibrosis:

Fibrosis (691 drugs)

Browse all the conditions that are associated with Fibrosis:

Fibrosis (682 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on iohexol (the active ingredients of Omnipaque 140) and Omnipaque 140 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.